Clinical trials in breast cancer; do we have the right approaches?

by Lønning, PE
Published 2000

TP53 and additional pathways in therapy resistance

by Lønning, PE
Published 2005

Relation of gene expression-based tumor subclasses to clinical phenotypes

by Sørlie, T, Perou, CM, Lønning, PE, Brown, PO, Botstein, D, Børresen-Dale, A-L
Published 2000

Expression of wild-type and mutated TP53 in breast carcinomas

by Baumbusch, LO, Myhre, S, Langerød, A, Bergamaschi, A, Johnsen, H, Geisler, S, Lønning, PE, Børresen-Dale, A-L
Published 2005

Genetic variants of CYP19 (aromatase) and breast cancer risk

by Nedelcheva Kristensen, V, Harada, N, Yoshimura, N, Haraldsen, E, Lønning, PE, Erikstein, B, Kåresen, R, Kristensen, T, Børresen-Dale, A-L
Published 2000

Screening breast cancer patients for Norwegian ATM mutations

by Laake, K, Vu, P, Andersen, TI, Erikstein, B, Kåresen, R, Lønning, PE, Skovlund, E, Børresen-Dale, A-L
Published 2000

p16INK4A as a predictive factor in patients with locally advanced breast cancer treated with neoadjuvant doxorubicin monotherapy

by Geisler, S, Smith-Sørensen, B, Betticher, D, Bukholm, IK, Akslen, LA, Kappeler, A, Gugger, M, Lønning, PE, Børresen-Dale, A-L
Published 2000

Comparison of methods for pharmacogenomics: SNaPshot, SNPstream UHT, Nanogen, and RFLP

by Alnæs, GIG, Johansen, FE, Nordgard, SH, Hihn, B, Edvardsen, H, Hilden, VI, Lønning, PE, Syvänen, A-C, Børresen-Dale, A-L, Kristensen, VN
Published 2005